An Extension Study for Patients Previously Treated With ARQ 501

Phase 1

Completed

• Conditions: Cancer

• Registration Number: NCT00622063
• Lead Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Brief Summary

To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501

Detailed Description

Not available

Study Timeline

• Study Start: 2006-12
• Study First Submitted: 2008-02-12
• Study First Submitted QC: 2008-02-12
• Study First Posted: 2008-02-22
• Primary Completion: 2008-09
• Status Verified: 2013-02
• Disposition First Submitted: 2013-02-21
• Disposition First Submitted QC: 2013-02-22
• Last Update Submitted: 2013-02-22
• Disposition First Posted: 2013-02-28
• Last Update Posted: 2013-02-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

• Signed written informed consent
• Has previous participated in a clinical trial with ARQ 501 and is eligible for continued treatment

Exclusion Criteria

• Have not received previous treatment with ARQ 501 under a treatment protocol
• Uncontrolled intercurrent illness, uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501	No time frame

Secondary Outcome Measures

Name	Time	Method
To collect additional safety and tolerability information for ARQ 501 treatment	No time frame

Trial Locations

Locations (1)

Mary Crowley Medical Research Center; 🇺🇸 Dallas, Texas, United States